<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>oncology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>oncology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer
Authors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/oncology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="oncology" />
<meta property="og:description" content="Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer
Authors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/oncology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2024-01-10T10:40:05+00:00" />
<meta property="article:modified_time" content="2024-01-10T10:40:05+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="oncology"/>
<meta name="twitter:description" content="Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer
Authors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "oncology",
      "item": "https://trxiv.yorks0n.com/posts/oncology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "oncology",
  "name": "oncology",
  "description": "Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer\nAuthors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G.",
  "keywords": [
    
  ],
  "articleBody": " Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer\nAuthors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G.; Spiro, P.; Ta, B.; Vitko, D.; Waiss, J.; Yanagihara, Z.; Zawada, R.; Zeng, J. Y.; Zhang, S.; Yee, J.; Blume, J. E.; Belthangady, C.; Wilcox, B.; Ma, P.\nScore: 29.5, Published: 2024-01-04 DOI: 10.1101/2024.01.03.24300798\nBlood-based approaches to detect early-stage cancer provide an opportunity to improve survival rates for lung cancer, the most lethal cancer world-wide. Multiple approaches for blood-based cancer detection using molecular analytes derived from individual omics (cell-free DNA, RNA transcripts, proteins, metabolites) have been developed and tested, generally showing significantly lower sensitivity for early-stage versus late-stage cancer. We hypothesized that an approach using multiple types of molecular analytes, including broad and untargeted coverage of proteins, could identify biomarkers that more directly reveal changes in gene expression and molecular phenotype in response to carcinogenesis to potentially improve detection of early-stage lung cancer. To that end, we designed and conducted one of the largest multi-omics, observational studies to date, enrolling 2513 case and control subjects. Multi-omics profiling detected 113,671 peptides corresponding to 8385 protein groups, 219,729 RNA transcripts, 71,756 RNA introns, and 1801 metabolites across all subject samples. We then developed a machine learning-based classifier for lung cancer detection comprising 682 of these multi-omics analytes. This multi-omics classifier demonstrated 89%, 80%, and 98-100% sensitivity for all-stage, stage I, and stage III-IV lung cancer, respectively, at 89% specificity in a validation set. The application of a multi-omics platform for discovery of blood-based disease biomarkers, including proteins and complementary molecular analytes, enables the noninvasive detection of early-stage lung cancer with the potential for downstaging at initial diagnosis and the improvement of clinical outcomes.\nMachine learning enabled prediction of digital biomarkers from whole slide histopathology images\nAuthors: McCaw, Z. R.; Shcherbina, A.; Shah, Y.; Huang, D.; Elliott, S.; Szabo, P. M.; Dulken, B.; Holland, S.; Tagari, P.; Light, D.; Koller, D.; Probert, C.\nScore: 7.3, Published: 2024-01-09 DOI: 10.1101/2024.01.06.24300926\nCurrent predictive biomarkers generally leverage technologies such as immunohistochemistry or genetic analysis, which may require specialized equipment, be time-intensive to deploy, or incur human error. In this paper, we present an alternative approach for the development and deployment of a class of predictive biomarkers, leveraging deep learning on digital images of hematoxylin and eosin (H\u0026E)-stained biopsy samples to simultaneously predict a range of molecular factors that are relevant to treatment selection and response. Our framework begins with the training of a pan-solid tumor H\u0026E foundation model, which can generate a universal featurization of H\u0026E-stained tissue images. This featurization becomes the input to machine learning models that perform multi-target, pan-cancer imputation. For a set of 352 drug targets, we show the ability to predict with high accuracy: copy number amplifications, target RNA expression, and an RNA-derived \"amplification signature\" that captures the transcriptional consequences of an amplification event. We facilitate exploratory analyses by making broad predictions initially. Having identified the subset of biomarkers relevant to a patient population of interest, we develop specialized machine learning models, built on the same foundational featurization, which achieve even higher performance for key biomarkers in tumor types of interest. Moreover, our models are robust, generalizing with minimal loss of performance across different patient populations. By generating imputations from tile-level featurizations, we enable spatial overlays of molecular annotations on top of whole-slide images. These annotation maps provide a clear means of interpreting the histological correlates of our model's predictions, and align with features identified by expert pathologist review. Overall, our work demonstrates a flexible and scalable framework for imputing molecular measurements from H\u0026E, providing a generalizable approach to the development and deployment of predictive biomarkers for targeted therapeutics in cancer.\nMapping inherited genetic variation with opposite effects on autoimmune disease and cancer identifies candidate drug targets associated with the anti-tumor immune response\nAuthors: Chen, J.; Epstein, M. P.; Schildkraut, J. M.; Kar, S. P.\nScore: 8.7, Published: 2023-12-28 DOI: 10.1101/2023.12.23.23300491\nBackgroundGermline alleles near genes that encode certain immune checkpoints (CTLA4, CD200) are associated with autoimmune/autoinflammatory disease and cancer but in opposite directions. This motivates a systematic search for additional germline alleles which demonstrate this pattern with the aim of identifying potential cancer immunotherapeutic targets using human genetic evidence. MethodsPairwise fixed effect cross-disorder meta-analyses combining genome-wide association studies (GWAS) for breast, prostate, ovarian and endometrial cancers (240,540 cases/317,000 controls) and seven autoimmune/autoinflammatory diseases (112,631 cases/895,386 controls) coupled with in silico follow-up. To ensure detection of alleles with opposite effects on cancer and autoimmune/autoinflammatory disease, the signs on the beta coefficients in the autoimmune/autoinflammatory GWAS were reversed prior to meta-analyses. ResultsMeta-analyses followed by linkage disequilibrium clumping identified 312 unique, independent lead variants with Pmeta\u003c5x10-8 associated with at least one of the cancer types at Pcancer\u003c10-3 and one of the autoimmune/autoinflammatory diseases at Pauto\u003c10-3. At each lead variant, the allele that conferred autoimmune/autoinflammatory disease risk was protective for cancer. Mapping each lead variant to its nearest gene as its putative functional target and focusing on genes with established immunological effects implicated 32 of the nearest genes. Tumor bulk RNA-Seq data highlighted that the tumor expression of 5/32 genes (IRF1, IKZF1, SPI1, SH2B3, LAT) were each strongly correlated (Spearmans {rho}\u003e0.5) with at least one intra-tumor T/myeloid cell infiltration marker (CD4, CD8A, CD11B, CD45) in every one of the cancer types. Tumor single-cell RNA-Seq data from all cancer types showed that the five genes were more likely to be expressed in intra-tumor immune versus malignant cells. The five lead SNPs corresponding to these genes were linked to them via expression quantitative trait locus mechanisms and at least one additional line of functional evidence. Proteins encoded by the genes were predicted to be druggable. ConclusionWe provide population-scale germline genetic and functional genomic evidence to support further evaluation of the proteins encoded by IRF1, IKZF1, SPI1, SH2B3, and LAT as possible targets for cancer immunotherapy.\n",
  "wordCount" : "1017",
  "inLanguage": "en",
  "datePublished": "2024-01-10T10:40:05Z",
  "dateModified": "2024-01-10T10:40:05Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/oncology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      oncology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on January 10, 2024&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.03.24300798">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.03.24300798" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.03.24300798">
        <p class="paperTitle">Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.03.24300798" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.03.24300798" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G.; Spiro, P.; Ta, B.; Vitko, D.; Waiss, J.; Yanagihara, Z.; Zawada, R.; Zeng, J. Y.; Zhang, S.; Yee, J.; Blume, J. E.; Belthangady, C.; Wilcox, B.; Ma, P.</p>
        <p class="info">Score: 29.5, Published: 2024-01-04 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.03.24300798' target='https://doi.org/10.1101/2024.01.03.24300798'> 10.1101/2024.01.03.24300798</a></p>
        <p class="abstract">Blood-based approaches to detect early-stage cancer provide an opportunity to improve survival rates for lung cancer, the most lethal cancer world-wide. Multiple approaches for blood-based cancer detection using molecular analytes derived from individual  omics (cell-free DNA, RNA transcripts, proteins, metabolites) have been developed and tested, generally showing significantly lower sensitivity for early-stage versus late-stage cancer. We hypothesized that an approach using multiple types of molecular analytes, including broad and untargeted coverage of proteins, could identify biomarkers that more directly reveal changes in gene expression and molecular phenotype in response to carcinogenesis to potentially improve detection of early-stage lung cancer. To that end, we designed and conducted one of the largest multi-omics, observational studies to date, enrolling 2513 case and control subjects. Multi-omics profiling detected 113,671 peptides corresponding to 8385 protein groups, 219,729 RNA transcripts, 71,756 RNA introns, and 1801 metabolites across all subject samples. We then developed a machine learning-based classifier for lung cancer detection comprising 682 of these multi-omics analytes. This multi-omics classifier demonstrated 89%, 80%, and 98-100% sensitivity for all-stage, stage I, and stage III-IV lung cancer, respectively, at 89% specificity in a validation set. The application of a multi-omics platform for discovery of blood-based disease biomarkers, including proteins and complementary molecular analytes, enables the noninvasive detection of early-stage lung cancer with the potential for downstaging at initial diagnosis and the improvement of clinical outcomes.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.06.24300926">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.06.24300926" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.06.24300926">
        <p class="paperTitle">Machine learning enabled prediction of digital biomarkers from whole slide histopathology images</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.06.24300926" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.06.24300926" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: McCaw, Z. R.; Shcherbina, A.; Shah, Y.; Huang, D.; Elliott, S.; Szabo, P. M.; Dulken, B.; Holland, S.; Tagari, P.; Light, D.; Koller, D.; Probert, C.</p>
        <p class="info">Score: 7.3, Published: 2024-01-09 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.06.24300926' target='https://doi.org/10.1101/2024.01.06.24300926'> 10.1101/2024.01.06.24300926</a></p>
        <p class="abstract">Current predictive biomarkers generally leverage technologies such as immunohistochemistry or genetic analysis, which may require specialized equipment, be time-intensive to deploy, or incur human error. In this paper, we present an alternative approach for the development and deployment of a class of predictive biomarkers, leveraging deep learning on digital images of hematoxylin and eosin (H&amp;E)-stained biopsy samples to simultaneously predict a range of molecular factors that are relevant to treatment selection and response. Our framework begins with the training of a pan-solid tumor H&amp;E foundation model, which can generate a universal featurization of H&amp;E-stained tissue images. This featurization becomes the input to machine learning models that perform multi-target, pan-cancer imputation. For a set of 352 drug targets, we show the ability to predict with high accuracy: copy number amplifications, target RNA expression, and an RNA-derived &#34;amplification signature&#34; that captures the transcriptional consequences of an amplification event. We facilitate exploratory analyses by making broad predictions initially. Having identified the subset of biomarkers relevant to a patient population of interest, we develop specialized machine learning models, built on the same foundational featurization, which achieve even higher performance for key biomarkers in tumor types of interest. Moreover, our models are robust, generalizing with minimal loss of performance across different patient populations. By generating imputations from tile-level featurizations, we enable spatial overlays of molecular annotations on top of whole-slide images. These annotation maps provide a clear means of interpreting the histological correlates of our model&#39;s predictions, and align with features identified by expert pathologist review. Overall, our work demonstrates a flexible and scalable framework for imputing molecular measurements from H&amp;E, providing a generalizable approach to the development and deployment of predictive biomarkers for targeted therapeutics in cancer.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.23.23300491">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.23.23300491" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.23.23300491">
        <p class="paperTitle">Mapping inherited genetic variation with opposite effects on autoimmune disease and cancer identifies candidate drug targets associated with the anti-tumor immune response</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.23.23300491" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.23.23300491" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Chen, J.; Epstein, M. P.; Schildkraut, J. M.; Kar, S. P.</p>
        <p class="info">Score: 8.7, Published: 2023-12-28 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.23.23300491' target='https://doi.org/10.1101/2023.12.23.23300491'> 10.1101/2023.12.23.23300491</a></p>
        <p class="abstract">BackgroundGermline alleles near genes that encode certain immune checkpoints (CTLA4, CD200) are associated with autoimmune/autoinflammatory disease and cancer but in opposite directions. This motivates a systematic search for additional germline alleles which demonstrate this pattern with the aim of identifying potential cancer immunotherapeutic targets using human genetic evidence.

MethodsPairwise fixed effect cross-disorder meta-analyses combining genome-wide association studies (GWAS) for breast, prostate, ovarian and endometrial cancers (240,540 cases/317,000 controls) and seven autoimmune/autoinflammatory diseases (112,631 cases/895,386 controls) coupled with in silico follow-up. To ensure detection of alleles with opposite effects on cancer and autoimmune/autoinflammatory disease, the signs on the beta coefficients in the autoimmune/autoinflammatory GWAS were reversed prior to meta-analyses.

ResultsMeta-analyses followed by linkage disequilibrium clumping identified 312 unique, independent lead variants with Pmeta&lt;5x10-8 associated with at least one of the cancer types at Pcancer&lt;10-3 and one of the autoimmune/autoinflammatory diseases at Pauto&lt;10-3. At each lead variant, the allele that conferred autoimmune/autoinflammatory disease risk was protective for cancer. Mapping each lead variant to its nearest gene as its putative functional target and focusing on genes with established immunological effects implicated 32 of the nearest genes. Tumor bulk RNA-Seq data highlighted that the tumor expression of 5/32 genes (IRF1, IKZF1, SPI1, SH2B3, LAT) were each strongly correlated (Spearmans {rho}&gt;0.5) with at least one intra-tumor T/myeloid cell infiltration marker (CD4, CD8A, CD11B, CD45) in every one of the cancer types. Tumor single-cell RNA-Seq data from all cancer types showed that the five genes were more likely to be expressed in intra-tumor immune versus malignant cells. The five lead SNPs corresponding to these genes were linked to them via expression quantitative trait locus mechanisms and at least one additional line of functional evidence. Proteins encoded by the genes were predicted to be druggable.

ConclusionWe provide population-scale germline genetic and functional genomic evidence to support further evaluation of the proteins encoded by IRF1, IKZF1, SPI1, SH2B3, and LAT as possible targets for cancer immunotherapy.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2024 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
